Clinical Trials for Other Solid Tumor

A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-303, as Monotherapy and in Combination With Budigalimab (ABBV-181), in Adult Subjects With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial includes adult patients with relapsed or refractory advanced solid tumors, such as non-small cell lung cancer, renal cell carcinoma, and head and neck squamous cell carcinoma, who have an ECOG performance status of 0 or 1. It evaluates the safety and efficacy of ABBV-303, a trispecific killer cell engager targeting c-Met, as monotherapy and in combination with budigalimab, a PD-1 inhibitor.

ClinicalTrials.gov ID: NCT06158958

A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial involves patients aged 18 or older with stage IV non-squamous NSCLC, comparing the investigational PD-1 targeting antibody ABP 234 to pembrolizumab, both combined with pemetrexed and either cisplatin or carboplatin chemotherapy. Participants must have measurable disease without prior advanced systemic treatment and meet specific biomarker and genetic criteria.

ClinicalTrials.gov ID: NCT06311721

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) in Participants with Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic melanoma or relapsed refractory metastatic non-small cell lung cancer who have progressed after specific therapies, and it tests OBX-115, a membrane-bound IL15 expressing tumor-infiltrating lymphocyte regimen designed to enhance anti-cancer immune responses.

ClinicalTrials.gov ID: NCT06060613

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the novel KRAS G12D inhibitor RMC-9805, alone and with the multi-selective RAS inhibitor RMC-6236, in adult patients with advanced KRAS G12D-mutant solid tumors, including those who have progressed on standard therapies and have an ECOG status of 0 or 1.

ClinicalTrials.gov ID: NCT06040541

A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates BDTX-1535, an oral, brain-penetrant, irreversible EGFR inhibitor, in adult patients with advanced/metastatic NSCLC with specific resistance EGFR mutations and GBM patients with EGFR alterations, assessing its safety, dosage, CNS activity, and efficacy.

ClinicalTrials.gov ID: NCT05256290

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

HealthScout AI summary: This trial involves patients with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer, comparing the investigational next-generation TKI repotrectinib, targeting ROS1 and other kinases, with standard treatment crizotinib. Eligible patients must have a confirmed ROS1 gene rearrangement and no prior exposure to TKIs effective in ROS1-positive NSCLC, with an ECOG Performance Status of 2 or less.

ClinicalTrials.gov ID: NCT06140836

A Phase 1, Multicenter, Open-label, First-in-human Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves the antibody-drug conjugate YL202, targeting the HER3 protein and delivering a cytotoxic topoisomerase I inhibitor, in patients with locally advanced or metastatic EGFR-mutated NSCLC or hormone receptor-positive, HER2-negative breast cancer who have undergone prior standard treatments. The study focuses on evaluating the safety and early efficacy through varying dosages of YL202.

ClinicalTrials.gov ID: NCT05653752

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced or metastatic malignancies, including specific subsets like STK11m mutated NSCLC, testing AB801, an AXL receptor tyrosine kinase inhibitor, alone and in combination with zimberelimab (a PD-1 inhibitor) and docetaxel. Participants must have an ECOG performance status of 0 or 1 and lack remaining standard treatment options.

ClinicalTrials.gov ID: NCT06120075

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors that are metastatic, locally advanced, recurrent, or inoperable, who have no effective standard therapy options left, exploring [225Ac]-FPI-2068 for targeted alpha therapy, [111In]-FPI-2107 for tumor imaging, and FPI-2053, a bispecific antibody targeting EGFR and c-MET, for potential combinational treatment.

ClinicalTrials.gov ID: NCT06147037

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects With Metastatic or Unresectable Non-Small Cell Lung Cancer and Other Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves patients with metastatic or unresectable non-small cell lung cancer and other solid tumors who receive BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3, designed with a novel topoisomerase I inhibitor payload. The study evaluates different dosing schedules to determine safety, tolerability, and efficacy, particularly aiming to optimize dosing based on promising response rates in EGFR-mutated NSCLC and other cancer types.

ClinicalTrials.gov ID: NCT05983432